Bladder cancer highlights at ASCO 2022

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, provides an overview of key areas of unmet need in patients with muscle-invasive bladder cancer, including the long-term outcomes of EV-301 (NCT03474107), a Phase III trial evaluating enfortumab vedotin in previously treated advanced urothelial carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.